

1 **Gene-by-environment interactions are** 2 **pervasive among natural genetic variants**

3 Shi-An A. Chen*¹, Alexander F. Kern*², Roy Moh Lik Ang², Yihua Xie¹, Hunter B. Fraser^{1†}

4 *Equal Contribution

5 ¹Department of Biology, Stanford University, Stanford, CA 94305, USA

6 ²Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305,
7 USA

8 † Correspondence: Hunter B. Fraser ([hbfraser@stanford.edu](mailto:h Fraser@stanford.edu))

9 **Summary**

10 Gene-by-Environment (GxE) interactions are fundamental to understanding fitness
11 landscapes and evolution, but have been difficult to identify at the single-nucleotide level,
12 precluding understanding of their prevalence and molecular mechanisms. Most
13 examples involving natural genetic variants exist at the level of entire genomes, e.g.
14 measurement of microbial strain growth across environments, or loci encompassing
15 many variants identified by quantitative trait loci mapping. Here, we introduce CRISPEY-
16 BAR, a high-throughput precision-editing strategy, and use it to map base-pair resolution
17 GxE interactions impacting yeast growth under stress conditions. First, we used
18 CRISPEY-BAR to uncover 338 variants with fitness effects within QTLs previously
19 mapped in different environments. We then measured 1432 ergosterol pathway variants
20 from diverse lineages across six environments, identifying 205 natural variants affecting
21 fitness measured in all six conditions, of which 93.7% showed GxE interactions. Finally,
22 we examine pleiotropic cis-regulatory variants suggesting molecular mechanisms of GxE
23 interaction. In sum, our results suggest an extremely complex, context-dependent fitness
24 landscape characterized by pervasive GxE interactions, while also demonstrating high-
25 throughput genome editing as an effective means for investigating this complexity.

26

27 **Introduction**

28 An important issue in understanding complex traits is the phenomenon of gene-by-
29 environment (GxE) interactions, wherein a genetic variant's effect is dependent on the
30 environment an organism is exposed to (Grishkevich and Yanai, 2013). For example,
31 humans heterozygous for the sickle cell allele of beta-globin have a fitness advantage in
32 environments that include malaria, and those with a lactase persistence allele have a
33 fitness advantage when consuming dairy products (Luzzatto, 2012; Tishkoff et al., 2007).
34 Identifying the genetic basis of such interactions is a key challenge in biology and is
35 essential to the fields of medicine, genetics, synthetic biology, and evolutionary biology
36 (Cardinale and Arkin, 2012; Li et al., 2019; Via and Lande, 1985).

37
38 Studies for identifying GxE generally come in two main varieties: forward and reverse
39 genetic approaches. Forward genetic approaches leverage the association of natural
40 variation to observed traits, which can be as simple as measuring the environmental
41 response of different strains or species. With enough samples across multiple
42 environments, genome-wide association studies (GWAS) can detect signals of GxE
43 (Peter et al., 2018). Alternatively, quantitative trait locus (QTL) mapping uses genetic
44 crosses between strains to create diverse progeny through recombination to calculate
45 statistical signals that associate with environmental response (Bloom et al., 2013, 2019;
46 Ehrenreich et al., 2012; Smith and Kruglyak, 2008). However, it is generally impossible
47 to identify the specific variants underlying a GWAS or QTL peak without laborious follow-
48 up experiments, due to insufficient mapping resolution, though crosses with tens of
49 thousands of recombinant genotypes can resolve some QTLs to single nucleotides
50 (Nguyen Ba et al., 2022; Rockman, 2012; She and Jarosz, 2018).

51
52 On the other hand, reverse genetic approaches such as constructing knockout libraries
53 and measuring their effects on growth have single-gene resolution, and have been
54 invaluable sources of information about the functions of genes in various organisms and
55 their genetic interactions. However, most reverse genetics approaches to identify GxE
56 interactions assay artificial alleles, such as gene knockouts or over-expression cassettes

57 (Hillenmeyer et al., 2008; Jones et al., 2008). These generally do not reflect naturally
58 occurring variants that contribute to phenotypic variation, so it is unknown whether GxE
59 interactions of these alleles are relevant for understanding evolution. In some cases,
60 reciprocal hemizyosity assays have been able to replace whole genes for dissecting
61 QTL traits, but have not been able to separate the many variants within each gene
62 (Smith and Kruglyak, 2008; Steinmetz et al., 2002). By using either forward or reverse
63 genetic approaches alone, it is still a challenge to find the precise variants that underlie
64 GxE (Ehrenreich et al., 2012).

65

66 Here, we combine the merits of forward and reverse genetics—integrating natural
67 variation with massively parallel reverse genetic screens—to uncover variants harboring
68 GxE interactions at the single nucleotide level. Previously, we showed that Cas9 Retron
69 preclSe Parallel Editing via homologY (CRISPEY) can achieve high efficiency precise
70 editing, by utilizing a bacterial retron reverse transcriptase (RT) to generate multi-copy,
71 single-stranded DNA (msDNA) from RNA templates *in nucleo* to facilitate homology-
72 directed repair after Cas9-mediated genomic DNA cleavage (Sharon et al., 2018). To
73 this end we created CRISPEY-BAR, a platform for creating and monitoring thousands of
74 genetic variants in a single experiment. This is achieved through multiplexed,
75 programmed installation of a predefined variant and an associated non-random barcode
76 using a dual-CRISPEY design. Importantly, this design has improved statistical power to
77 detect fitness effects by incorporating unique molecular identifiers (UMIs), as well as the
78 ability to maintain strain barcodes in non-selective media, enabling us to both assay and
79 detect GxE effects of thousands of individual genetic variants in any growth condition.
80 This approach allows us to survey natural variants throughout the genome in any
81 condition, giving us the ability to decipher the precise genetic basis and molecular
82 mechanisms giving rise to complex traits.

83

84 We used CRISPEY-BAR to measure the effects of 4184 natural variants segregating in
85 yeast (*Saccharomyces cerevisiae*) across a variety of conditions. We pinpointed 548
86 variants underlying variation in growth in these environments. Importantly, the resolution
87 of our measurements can differentiate the effects of variants even when they are tightly

88 clustered in the genome, as well as different alleles at the same genomic position. This
89 single-nucleotide resolution of GxE interactions not only allows us to explore the natural
90 landscape of complex traits, but also provides direct mechanistic insights into phenotypic
91 evolution (Lee et al., 2014; Rockman, 2012). More generally, we have established a
92 paradigm for studying genetic variants and their environmental interactions at
93 unprecedented resolution and throughput via multiplexed precision genome editing.

94

95

96 **Results**

97 **CRISPEY-BAR enables high-resolution mapping of genotype to phenotype** 98 **relationships**

99 CRISPEY-BAR is a scalable system for measuring the effects of precise genome edits
100 by tracking an associated genomic barcode (**Figure 1a**). As described in our previous
101 report, CRISPEY uses a single guide/donor pair to make one precise edit per cell, and in
102 a pooled assay, measures the change in abundance of each guide/donor pair post-
103 editing through high-throughput sequencing of plasmids (**Figure 1b**) (Sharon et al.,
104 2018). We developed a new vector design incorporating two consecutive retron-guide
105 cassettes flanked by three self-cleaving ribozymes, allowing simultaneous generation of
106 two guide/donor pairs for making two precise edits in the same cell (Riccitelli et al., 2014)
107 (**Figure 1a, Supplemental Figure 1**). The different ribozymes prevent unwanted
108 recombination events during pooled cloning and co-transcriptionally separate the two
109 retron-guide RNAs for processing by retron reverse transcriptase (RT). CRISPEY-BAR
110 implements a dual-edit design to simultaneously 1) integrate a unique genomic barcode
111 and 2) make a precise variant edit of interest. Each variant editing guide/donor pair is
112 associated with a unique barcode, which can be used to track change in the abundance
113 of cells edited by a specific guide/donor pair (**Figure 1c**). Importantly, we further linked
114 UMIs to each barcode, to serve as biological replicates for pooled-editing and growth
115 competition (**Figure 1c**). We designed CRISPEY-BAR to measure the fitness effect of
116 each variant with at least two guide/donor pairs, six UMIs and three pooled competition
117 replicates (**Figure 1c, Supplemental Figure S2**).

118
119 Since the barcode is genomically-integrated, no maintenance of an ectopic vector is
120 needed post-editing, and 1:1 stoichiometric measurement of edited strains can be
121 achieved through multiplexed sequencing of barcode amplicons (**Figure 1d**). In
122 particular, the barcode was designed to be covered by 76-base short-read sequencing to
123 minimize sequencing costs and run-time, instead of resequencing the plasmid with 300-
124 base paired-end reads to re-identify guide-donor pairs (**Supplemental Figure S3**). This
125 sequencing design uses primers that are specific to the barcode-integrated genomic

126 locus, therefore sequencing only the barcoded strains (**Supplemental Figure S3**).
127 Selective detection of the integrated barcode edit guarantees the edited cell expresses
128 functional Cas9 and retron components, as well as endogenous cellular factors that
129 facilitate HDR. This strategy allowed us to enrich for strains likely containing variant
130 edits, which is crucial for high-throughput screens. A similar co-CRISPR strategy has
131 been shown to improve edited mutant selection by co-injection of multiple editing vectors
132 for both non-selectable and selectable-markers (Kim et al., 2014). We found an
133 aggregate 92% pooled editing rate from randomly picked barcoded strains (**Figure 1e**).
134

135 The genome-integrated barcodes from a multiplexed CRISPEY-BAR library enabled us
136 to track the abundance of thousands of programmed mutants in non-selective media
137 (**Figure 1f,g**). Importantly, we included no-edit controls that do not install any variants
138 apart from barcode integration to establish neutral fitness levels that arise from experi-
139 mental noise and genetic drift (**Figure 1f,g**). Six pre-defined unique molecular identifiers
140 (UMIs) were incorporated for every barcode-variant edit combination to increase biologi-
141 cal replication, allowing us to capture the noise from variable editing rates due to guide
142 efficiency as well as outlier detection of random mutants arising during transformation,
143 editing, and competition to improve our estimates of variant fitness effects (**Figure 1h**).
144 Spontaneous mutations with strong positive fitness effects in particular would be ex-
145 pected to dominate the reads for a given UMI, so by removing these potential outlier
146 UMIs, we sought to reduce false positives (**STAR Methods**). We reasoned that it is un-
147 likely that random mutations would arise for all UMI replicates for a given variant edit in-
148 dependent of CRISPEY-BAR.

149 We were able to show that CRISPEY-BAR measured fitness effects are highly reproduci-
150 ble between growth competition replicates. Variant fitness is approximated by fitting a lin-
151 ear model for estimating log₂ fold-change abundance of each barcode-UMI over genera-
152 tion time during growth competition, as described previously (Pearson $r = 0.9996$, $p =$
153 1.38×10^{-16} for variants with $FDR < 0.25$ in both replicates) (**Figure 1i**, see also **STAR**
154 **Methods**) (Sharon et al., 2018). Importantly, across four independently generated and
155 measured variant pools, measured in 13 competitions, only four putatively non-targeting

156 barcodes had significant fitness effects in any competition at $FDR < 0.01$, out of 43 in
157 each pool, showing that CRISPEY-BAR has a low false positive rate. In addition,
158 CRISPEY-BAR measured fitness effects are highly reproducible between experiments.
159 Overlapping variants from two separately cloned, transformed, edit-induced, growth-
160 completed, library-prepared, and sequenced CRISPEY-BAR experiments showed high
161 replication (Pearson $r = 0.979$, $p = 1.52 \times 10^{-7}$ for all overlapping variants) in fitness effects
162 for growth in cobalt chloride, despite being competed against an otherwise separate li-
163 brary other than technical controls (**Figure 1j**). This result shows that with overlapping
164 variants between CRISPEY-BAR libraries, we can potentially scale pooled screening
165 strategies with minimal batch effects. Finally, we validated 13 genotyped strains edited
166 by CRISPEY-BAR and performed pairwise competitions in fluconazole versus a fluores-
167 cently labeled un-edited strain. The variant fitness measured by these pairwise competi-
168 tions showed a high correlation with fitness measured in pooled competitions (Pearson r
169 $= 0.940$, $p = 1.80 \times 10^{-6}$) (**Figure 1k**). In sum, CRISPEY-BAR is highly efficient in precision
170 editing and allows massively parallel tracking of variant fitness effects using the dual-edit
171 design.

172

173 **Detection of natural variants affecting fitness within QTLs reveals hidden genetic** 174 **complexity**

175 To evaluate CRISPEY-BAR as a high-throughput, scalable platform to measure variants' ef-
176 fects on phenotypes, we first sought to characterize variants within regions likely to be en-
177 riched for effects on growth in response to stress conditions, in which the yeast pool has
178 slower growth overall. We targeted a total of 36 genomic regions overlapping QTLs for
179 growth of segregants derived from 16 diverse parental strains, measured in three stress
180 conditions: fluconazole (FLC), cobalt chloride (CoCl_2) and caffeine (CAFF) (**Figure 2a**)
181 (Bloom et al., 2019). For each stress condition, we constructed a CRISPEY-BAR library
182 pool that targets natural variants that fall within previously identified genomic regions
183 identified by QTL mapping to affect growth in the corresponding stress condition (Bloom
184 et al., 2019; Peter et al., 2018). We selected QTLs with 1.5-LOD confidence intervals
185 containing only a single gene to not only increase the probability of finding fitness
186 variants affecting fitness, but also maximize the number of QTLs surveyed given a set

187 library size (Bloom et al., 2019). We reasoned that by installing diverse natural variants—
188 including many not present in the 16 parental strains—we would enrich for variants
189 impacting fitness in these stress conditions (**Figure 2a**) (Peter et al., 2018). We designed
190 3 oligonucleotide pools (corresponding to variants to be assayed in fluconazole, cobalt
191 chloride, and caffeine) for pooled cloning into 3 separate CRISPEY-BAR libraries, which
192 were then used for pooled editing (**STAR Methods**). After plasmid removal, we
193 subjected the edited yeast to pooled growth competitions in synthetic complete media as
194 well as each corresponding stress condition and tracked changes in barcode abundance
195 across roughly 25 generations (**Figure 2b, Supplemental Figure S2**). To ensure the
196 stress conditions were applied during yeast growth, we calibrated the dose of stress
197 agents (fluconazole, cobalt chloride, and caffeine) so that the average growth rate is
198 lower by 50% (**STAR Methods**). Importantly, we included barcodes with a non-targeting
199 guide (designed to target a sequence which is not present in these strains) as no-edit
200 controls to define the neutral fitness distribution within each pooled competition
201 experiment (**Figure 1f,g; STAR Methods**).

202

203 We identified 152 variants with significant fitness effects in fluconazole, 84
204 variants for cobalt chloride and 102 variants for caffeine within the regions screened for
205 each stress condition (FDR<0.01). We found substantially fewer variants with significant
206 fitness effects for growth in synthetic complete media (SC) than in the stress condition
207 for each of these pools (**Figure 2c**). We next sought to identify what types of variants
208 were most likely to have significant effects on fitness within these pools, leveraging the
209 single-nucleotide resolution of the measurements, and saw a substantial enrichment for
210 missense variants among causal variants in the drug conditions for all three libraries
211 (Fisher's exact test $p = 4.72 \times 10^{-3}$ for cobalt chloride, 1.20×10^{-6} for fluconazole, 1.31×10^{-29}
212 for caffeine) (**Figure 2d**). Within many of the QTLs we identified dozens of causal
213 variants (**Figure 2e**). For instance, 65 out of the 66 causal variants in *MAM3* for growth
214 in cobalt chloride increased fitness, indicating that they may impair function of this gene,
215 as *MAM3* knockout increases resistance to cobalt chloride (Yang et al., 2005). For other
216 QTL genes such as *TOR2*, the knockout of which has been shown to decrease fitness in
217 the presence of caffeine, we identified many variants both increasing and decreasing

218 fitness (Reinke et al., 2006). The base-pair level resolution of CRISPEY-BAR enables us
219 to identify substantial genetic complexity hidden within these QTLs.

220

221 One QTL gene, *PDR5*, was shared between our caffeine and fluconazole pools. This
222 well-studied multi-drug transporter had multiple variants affecting fitness in both
223 conditions, many of which had effects in the same direction between the conditions
224 (**Figure 2f**) (Balzi et al., 1994; Harris et al., 2021). For example, we were able to identify
225 two variants with fitness effect located one base-pair apart in the genome, both of which
226 cause missense changes to the same lysine residue in *PDR5* (**Figure 2g**). These two
227 variants both had substantial positive fitness effects for growth in fluconazole and
228 caffeine, and do not co-occur in strains within the 1011 yeast genomes collection,
229 indicating that they arose independently (Peter et al., 2018). One of these variants is
230 found almost exclusively in strains with the origin “Human, clinical,” while the other is
231 more broadly distributed across ecological origins. Beyond *PDR5*, there were several
232 other cases where two missense variants changed the same amino acid, both having
233 strong fitness effects (V136, G1967, and A2403 in *TOR1*, K768 in *TOR2*, G398 in *COT1*,
234 and N738 in *SWH1*).

235

236 To identify whether alleles with positive fitness effects in QTL conditions were enriched in
237 yeast strains from particular ecological origins, we counted the number of positive effect
238 alleles each strain in the 1,011 yeast genome strains had, including reference alleles
239 which were beneficial relative to the negative effect engineered variants (**STAR**
240 **Methods**). Interestingly, 41 of the top 100 scoring strains are from the ecological origins
241 “Human” and “Human, Clinical,” which is a substantial enrichment (hypergeometric p
242 $=1.41 \times 10^{-13}$). Notably these 41 strains came from four different clades. While this result
243 could be partially driven by population structure, it is also potentially suggestive of
244 selection for increased fluconazole resistance among yeast isolated from human origins,
245 warranting further study. This could be done by sampling variants from more regions of
246 the genome, focusing on variants with high allele frequencies in particular clades for
247 comparison.

248

249 **The GxE landscape of ergosterol synthesis pathway**

250 Having established the ability to identify multiple natural variants affecting fitness across
251 various environments with CRISPEY-BAR, we next examined GxE interactions within the
252 ergosterol biosynthesis pathway (Rodrigues, 2018). This essential metabolic pathway is
253 of great biomedical importance, being the target of multiple classes of antifungal drugs,
254 as well as statins and has also been shown to be affected by various other stress
255 conditions, owing to its complex transcriptional and post-transcriptional regulation
256 (**Figure 3a**) (Bhattacharya et al., 2018; Kern et al., 2021). We sought to test natural
257 variants within genes in this pathway as well as 1000 bp upstream and 500 bp
258 downstream of each ORF to capture promoters and downstream regulatory regions in
259 five stress conditions as well as SC media (**Figure 3b**). Across these six environments,
260 we were able to capture a total of 1432 variants passing minimum read filters and outlier
261 detection for at least one of the six conditions (**STAR Methods**).

262
263 Mapping of variants affecting fitness in our two drug conditions, lovastatin and
264 terbinafine, revealed that the target genes for these drugs (*HMG1/2* and *ERG1*
265 respectively) were enriched for variants showing strong fitness effects in these conditions
266 (lovastatin $p = 6.62 \times 10^{-12}$ and terbinafine $p = 1.55 \times 10^{-16}$, hypergeometric test) (**Figure 3c**)
267 (Jandrositz et al., 1991; Lum et al., 2004; Rine et al., 1983). This illustrates the specificity
268 of the variant effect measurements obtained from these screens. Notably, though these
269 conditions were enriched for variants with strong effects in the target genes, variants in
270 other ergosterol pathway genes also affected fitness, revealing extensive genetic
271 complexity. In addition, the variants with the strongest fitness effects in the different
272 conditions had different variant annotation enrichments. For instance, the 100 variants
273 with the strongest fitness effects in SC were enriched for upstream/promoter variants
274 (hypergeometric $p = 3.61 \times 10^{-3}$), while the 100 strongest effect variants in sodium chloride
275 were not (hypergeometric $p = 0.137$).

276
277 To identify GxE variants, we performed all pairwise comparisons between the relative
278 fitness measurements for each variant in each condition to see if the effects on growth
279 were significantly different (**Figure 3d,e**). To determine a reasonable threshold to define

280 GxE variants and see if our approach to identifying GxE was robust, we performed two
281 identical competitions in SC media and tested variants for GxE interactions between
282 them. With the significance threshold we used (FDR <0.01 and a change in sign of
283 fitness effect) there were zero variants showing significant GxE between the replicates,
284 compared to a mean of 44.3 for comparisons between conditions, suggesting that our
285 approach to identifying GxE has a low false positive rate. Since there were no significant
286 differences between SC replicates, we combined these replicate competitions in our final
287 analysis to increase statistical power. Overall, at this threshold we identified 256 distinct
288 variants with at least one significant GxE interaction (GxE variants), harboring 665
289 pairwise GxE interactions. We next examined annotation enrichments for GxE variants
290 and found that missense variants were strongly enriched (two-sided Bonferroni-corrected
291 hypergeometric $p = 2.09 \times 10^{-6}$), while synonymous variants were depleted (two-sided
292 Bonferroni-corrected hypergeometric $p = 1.70 \times 10^{-3}$) (**Figure 3f**).

293
294 The stringent definition of GxE above explicitly excludes variants with significantly
295 significant fitness effects which are in the same direction, which we term “magnitude
296 GxE” (red and pink in **Figure 3e**). While magnitude GxE is interesting, it also may be
297 highly dependent on many experimental variables such as drug concentration. Thus, we
298 opted for a stricter definition of a GxE variant: any variant with a significant GxE
299 interaction which has measured fitness effects in opposite directions in the two
300 conditions (blue in **Figure 3e**).

301
302 With CRISPEY-BAR, we were able to measure more than one variant at the same
303 genomic locus for multiallelic loci within the ergosterol pathway, which highlights the
304 resolution and specificity of the measurements. There were five multiallelic sites which
305 had a missense variant with a significant fitness effect in one or more of the growth
306 conditions. For three of these sites, the other variant was a synonymous variant with no
307 effects on fitness. For the other two sites, there was one site within *HMG2* where there
308 were two missense variants (C788F and C788Y), which had similar effects on fitness.
309 Strikingly, the other site in *HMG1* had two missense variants making P1033A and
310 P1033T changes which had significant effects in opposite directions on growth in

311 lovastatin, perhaps due to the different chemical properties of threonine (polar) and
312 alanine (nonpolar).

313

314 Next, we looked at the genomic locations of the GxE variants relative to one another to
315 see if there was any spatial structure to GxE. We defined significant GxE variants as
316 being within a cluster if they were located within a certain number of base pairs of
317 another significant GxE variant along the chromosome. For each variant type, we tested
318 if the GxE variants were more clustered than expected by chance at a variety of cluster
319 sizes/ using a permutation approach (**STAR Methods**). Upstream/promoter variants and
320 synonymous variants were significantly more clustered than expected by chance at a
321 range of cluster window sizes, while missense and downstream variants were not (**Fig,**
322 **S4**). Interestingly, upstream/promoter variants were most significantly clustered at
323 window sizes between 8 and 16 bp, which is similar to the size range of transcription
324 factor binding sites (TFBS) in yeast. We chose to focus on a window size of 8 bp, which
325 is roughly the average size of TFBS in yeast. At this distance, 36 out of 69 (52.2%)
326 promoter GxE variants (targeting 34 unique genomic positions) were within a cluster,
327 which is significantly more clustering of promoter GxE hit variants than expected by
328 chance (permutation $p = 0.002$). The 36 clustered promoter GxE variants are located in
329 14 clusters, with all clusters sharing at least one significant pairwise GxE interaction at a
330 relaxed threshold of $FDR < 0.1$, though not necessarily in the same direction.

331 Interestingly, the *HMG1* promoter had three of these clusters, all of which had significant
332 GxE interactions between caffeine and lovastatin, with strong effects on growth in
333 lovastatin in both directions (**Figure 3h**). Interestingly, five of these clusters overlapped
334 predicted transcription factor binding sites (TFBS) (Griffith et al., 2008; Harbison et al.,
335 2004; Pachkov et al., 2013). For the other clusters, they may disrupt TFBS which have
336 not been previously identified in the datasets we examined, perhaps due to context-
337 specific binding, or may affect fitness through another mechanism.

338

339 **Gene-by-Environment interactions are Pervasive Among Natural Variants**

340 Next, using our measurements of variant fitness effects in each condition, we examined
341 how prevalent GxE interactions were among natural variants with significant fitness

342 effects. If GxE interactions at the variant level were rare, we would expect to see that
343 variants with strong fitness effects in one condition would mostly have similar effects in
344 other conditions, and so would be correlated between conditions (**Figure 4a**).

345 Conversely, if GxE interactions were common, we would see little correlation between
346 fitness effects of the same variant in different conditions (**Figure 4b**). These patterns
347 would only be visible for variants with measurable fitness effects, as those that are
348 neutral or close enough to be not detected would be expected to show no correlation in
349 either case. We saw examples of both of these patterns in our data, with fitness effects
350 in caffeine and fluconazole within *PDR5* being generally well-correlated despite
351 differences in magnitude, while ergosterol pathway variants measured in lovastatin and
352 CoCl_2 showed little to no agreement (**Figure 4c,d**).

353
354 Checking the fraction of GxE among hits for two conditions at a time, the fraction of
355 variants with significant fitness effects in either condition with GxE interactions between
356 the conditions ranges from 24.4 to 71.4% for the ergosterol pool conditions. *PDR5*
357 variants in fluconazole and caffeine by this same method had 29.2% of significant
358 variants showing GxE (**Figure 4e**). Extending this analysis to examine effects in all
359 conditions for the ergosterol pathway variants, it is clear that almost all variants with
360 significant fitness effects showed GxE interactions (**Figure 4f**). Among all variants
361 measured in all six conditions which have at least one significant fitness effect in any
362 condition, 93.7% have significant GxE interactions (Bootstrap 99% confidence interval
363 88.8%-97.6%). This result is robust to the FDR threshold used to define significant
364 fitness effects and GxE interactions (**Figure S5**). In addition, this result is not solely
365 influenced by a single condition (**Figure S6**). It's important to note that having a strong
366 fitness effect in one condition would make it more likely for a variant to have a detectable
367 significant GxE interaction due to statistical power to detect a difference. However, if
368 there existed a class of variants that showed consistent fitness effects across the
369 conditions tested in magnitude and direction, they would have significant fitness effects
370 while not showing GxE. In contrast, if all conditions had a similar fraction of GxE variants
371 as the *PDR5* caffeine and fluconazole variants and were independent, only 82.2% ($1 -$
372 $(1 - .292)^5$) of variants would be expected to show GxE across six conditions. Strikingly,

373 these analyses show that the vast majority of the non-neutral variants in the ergosterol
374 biosynthesis pathway showed GxE, indicating that GxE interactions among natural
375 variants are pervasive in this pathway.

376

377 **Regulatory GxE interactions in the ergosterol pathway**

378 The finding that GxE interactions are pervasive among natural variants with detectable
379 fitness effects in the ergosterol synthesis pathway led us to further investigate the pattern
380 of their effects. In principle, the finding of pervasive GxE could be consistent with a
381 scenario in which most variants have fitness effects in only one condition and are neutral
382 in others (**Figure 5a**). In this case, we would expect to see that variants with a
383 significant fitness effect in one condition were no more likely than any other variant to
384 show a significant fitness effect in another, and so fitness effects across conditions
385 should be distributed independently across the variants. Conversely, if variants with
386 significant fitness effects in any condition were more likely to show strong fitness effects
387 in other conditions (i.e. be pleiotropic), we would expect that the fitness distributions for
388 the different conditions would not be independent, and significant fitness effects from
389 these conditions would be more “clustered” in certain variants than expected by chance.
390 15.0% of variants measured in all six conditions showed a strong fitness effect in at least
391 one condition, but 30.7% of variants that had a significant fitness effect in one condition
392 had a significant fitness effect in at least one other condition, a two-fold enrichment
393 (hypergeometric $p = 5.27 \times 10^{-10}$). These variants were further enriched for missense
394 variants relative to all GxE variants (hypergeometric $p = 5.40 \times 10^{-6}$), and further depleted
395 of synonymous variants (hypergeometric $p = 1.82 \times 10^{-3}$).

396

397 Variants with significant effects in more than one condition can be grouped into two
398 categories: 1) those with significant fitness effects in only one direction (**Figure 5b**) and
399 2) those with significant fitness effects in opposite directions, which we term “sign GxE”
400 (**Figure 5c**). Examining the strongest fitness effect for each of the variants with
401 significant effects, we observed that variants showing sign GxE had significantly higher
402 maximum effects than variants with significant effects in only one condition or multiple
403 conditions in the same direction (Mann-Whitney U-test $p=0.000193$ and $p=0.0367$

404 respectively) (**Figure 5d**). This indicates that variants with more drastic effects on fitness
405 in any given condition may be more likely to have fitness effects in the opposite direction
406 in another condition.

407
408 In many cases, our single-nucleotide resolution suggests plausible molecular
409 mechanisms underlying GxE. For example, we found that the pleiotropic variant
410 exhibiting sign GxE at chr7: 472522 C>A was located in a canonical Rpn4p binding site
411 (**Figure 5e**) (Foat et al., 2008; Mannhaupt et al., 1999). This variant's strongest effect
412 was a significant fitness decrease in lovastatin. Since Rpn4p is a transcriptional
413 activator, we hypothesized that the disruption of the Rpn4p binding site might decrease
414 *ERG4* expression. We used RT-qPCR to measure expression of *ERG4* in a genotyped
415 strain carrying chr7: 472522 C>A and found that its expression decreased relative to the
416 wildtype strain (**Figure 5e**). This decrease in expression agreed with *ERG4* expression in
417 a strain carrying a fully ablated Rpn4p TFBS, while a strain carrying an Rpn4p
418 consensus site had higher *ERG4* expression. Interestingly, a strain with another natural
419 variant that mutated a lower information base within the Rpn4p binding motif (chr7:
420 472525 T>A) showed a slight fitness decrease in lovastatin and did not show a
421 significant decrease in *ERG4* expression. Therefore, we reasoned that the chr7: 472522
422 C>A variant disrupted *ERG4* expression through mutation of the Rpn4p TFBS. We then
423 further tested the fitness in the Rpn4p consensus and Rpn4p mutated TFBS, showing
424 that *ERG4* expression correlated with fitness in lovastatin (**Figure S7**). In sum, we
425 showed that CRISPEY-BAR was able to survey thousands of natural variants and
426 identify the variants affecting fitness at the nucleotide-level, directly leading to discovery
427 of molecular mechanisms of GxE interactions.

428

429

430 Discussion

431 We demonstrated that the CRISPEY-BAR strategy and its applications provide a solution
432 to rapidly discover natural genetic variants impacting a complex trait. As a proof of
433 principle, we pinpointed 548 variants with significant effects on growth within QTLs, as
434 well as across a core metabolic pathway. Although we potentially expected QTLs to
435 contain variants with GxE interactions, it is surprising to uncover hidden complexity
436 among natural variants in close proximity to each other, which harbor fitness effects in
437 opposite directions (**Figure 2**). Within the ergosterol synthesis pathway, we were not
438 only able to find natural variants that facilitate differential drug responses, but also reveal
439 the pervasiveness of GxE interactions among variants with fitness effects across diverse
440 environmental challenges (**Figures 3, 4**). In future studies it will be interesting to see if
441 the pervasive GxE interactions we observed for the ergosterol pathway will apply to
442 additional pathways, growth conditions, and species.

443
444 We have demonstrated that pooled fitness measurements are reproducible across
445 CRISPEY-BAR experiments with only minimally overlapping sets of variants (**Figure 1j**).
446 This indicates that independent CRISPEY-BAR experiments with mostly separate sets of
447 variants may be directly compared by designing overlapping variants as fitness
448 standards between pools for joint analysis, allowing us to scale CRISPEY-BAR
449 experiments to explore a greater number of natural variants. Scaling up to cover variants
450 across entire genomes, we will be able to carry out even deeper probing of the
451 relationship between genotype and any trait amenable to pooled phenotyping (including
452 any traits that can be tied to growth or fluorescence-based reporters).

453
454 Deciphering the non-coding genome has been a major challenge even in just one
455 experimental condition and is further complicated by GxE interactions. In this study, we
456 showed that a class of variants with GxE cluster tightly within promoter regions, and
457 further found that some of them overlap known TFBS (**Figure 3g**). Although GxE
458 variants are most highly enriched in missense variants, we found no genomic clustering

459 of these protein-altering variants; elucidating their molecular mechanisms will be an
460 exciting area for future study.

461
462 CRISPEY-BAR is highly efficient in precise editing, and we envision multiple routes to
463 further improve its effectiveness. The RT was shown in CRISPEY to be effective in
464 production of msDNA as DNA donors for precision editing (Sharon et al., 2018). We
465 have since tested additional retron RTs in CRISPEY, showing higher efficiency in yeast,
466 as well as editing activity in human cells (Zhao et al., 2022). This study utilized the
467 SpCas9 with an 'NGG' PAM site, limiting the variants that can be targeted; however,
468 alternative nucleases with different PAM sequences can be interchanged with SpCas9 to
469 target additional variants (Hu et al., 2018; Legut et al., 2020; Nishimasu et al., 2018).

470
471 The CRISPEY-BAR approach has an efficient guide for barcoding, while the variant
472 editing guide can have a range of efficiency. Because we deployed two or more untested
473 guides to target each variant, we are more likely to believe that the guides that show the
474 same significant fitness effect were both efficient in making precise edits. Moreover, the
475 six UMIs allow outlier detection where spontaneous mutations or off-target effects may
476 have taken place. Combining guide reproducibility and UMI editing-competition
477 replication, every CRISPEY-BAR experiment allows us to accumulate data points for
478 supervised learning of effective guide design in CRISPEY-based editing strategies.

479
480 In this study, CRISPEY-BAR was applied to a lab strain of budding yeast to evaluate the
481 effect of natural variants. This may limit the portability of the fitness effects we measure
482 for individual variants, since they are only measured in this lab strain genetic
483 background. This caveat can be overcome by applying CRISPEY-BAR to additional
484 strains of budding yeast to not only capture the effects of variants within one lab strain,
485 but also the effect of genetic background (see companion paper by Ang *et al.*). Looking
486 ahead, the CRISPEY-BAR design also allows for additional ribozymes and CRISPEY
487 cassettes to be incorporated. A single barcode-insertion cassette plus two or more
488 variant editing cassettes can be expressed in the same transcript, allowing simultaneous
489 editing of two genetic variants of choice and integration of a variant-pair specific barcode.

490 With this design, we will be able to observe gene-by-gene (epistatic) interactions, as well
491 as gene-by-gene-by-environment (GxGxE) interactions that govern the crosstalk
492 between gene networks and the environment (Costanzo et al., 2016, 2021; Jaffe et al.,
493 2019).

494
495 The observation that GxE interactions were found to be pervasive among variants with
496 fitness effects in just six conditions tested was a surprising result. Most of the variants
497 with GxE have a significant effect in only one condition, which by definition shows GxE
498 with respect to the rest of the conditions. More excitingly, we found a fraction of the
499 variants to harbor sign GxE, which implies fitness tradeoffs in fluctuating environments
500 where selection acts in opposite directions on the variant (**Figure 4g**). Moreover, we
501 found a trend in which large-effect variants tend to also have larger effects in another
502 condition than expected by chance, forming a class of pleiotropic variants with two or
503 more conditional effects. While we expect additional variants with fitness effect to be
504 identified as more conditions or drug conditions are tested on the same set of variants, it
505 is intriguing to think that the pleiotropic variants may harbor disproportionate amounts of
506 environment-specific effects. If such is the case, by performing a limited set of CRISPEY-
507 BAR experiments with a diverse set of conditions, we will be able to prioritize a set of
508 pleiotropic variants that are likely to have effects in the remaining, untested conditions
509 spanning the phenotypic space.

510 **Acknowledgments**

511 We thank M.M. Desai, D. Petrov and members of the Fraser lab for helpful discussions.
512 S.A.C. was partially supported by Bio-X Stanford Interdisciplinary Graduate Fellowship,
513 NIH grant 1F31ES030282 and NIH 5T32GM007276-42. A.F.K. was partially supported by
514 NIH NHGRI Stanford Genomic Training Program 5T32HG000044. R.M.L.A. was partially
515 supported by the National Science Scholarship, from the Agency of Science, Technology
516 and Research (A*STAR). This work was supported by NIH grants 2R01GM097171,
517 1R01GM134228 and 1F31ES030282.

518

519 **Author Contributions**

520 Conceptualization, H.B.F., S.A.C and A.F.K.; Investigation, S.A.C., A.F.K., Y.X and H.B.F.;
521 Validation, S.A.C. and A.F.K.; Formal Analysis, S.A.C. and A.F.K.; Data curation, S.A.C.
522 and A.F.K.; Methodology, Software and Visualization, S.A.C., A.F.K. and R.M.L.A.; Writing
523 – Original Draft, S.A.C, A.F.K, H.B.F; Writing – Review & Editing, S.A.C, A.F.K, R.M.L.A.
524 and H.B.F; Funding Acquisition: S.A.C. and H.B.F.; Supervision H.B.F..

525

526 **Declaration of Interests**

527 H.B.F. is a co-inventor of a patent application describing the CRISPEY approach.

528

529 **References**

- 530 Balzi, E., Wang, M., Leterme, S., Van Dyck, L., and Goffeau, A. (1994). PDR5, a novel yeast multidrug
531 resistance conferring transporter controlled by the transcription regulator PDR1. *J. Biol. Chem.* *269*, 2206–
532 2214. .
- 533 Bao, Z., Hamedirad, M., Xue, P., Xiao, H., Tasan, I., Chao, R., Liang, J., and Zhao, H. (2018). Genome-
534 scale engineering of *Saccharomyces cerevisiae* with single-nucleotide precision. *Nat. Biotechnol.* *36*, 505–
535 508. <https://doi.org/10.1038/nbt.4132>.
- 536 Benjamini, Y., and Hochberg, Y. (1995). Controlling the False Discovery Rate: A Practical and Powerful
537 Approach to Multiple Testing. *J. R. Stat. Soc. Ser. B Methodol.* *57*, 289–300. .
- 538 Bhattacharya, S., Esquivel, B.D., and White, T.C. (2018). Overexpression or Deletion of Ergosterol
539 Biosynthesis Genes Alters Doubling Time, Response to Stress Agents, and Drug Susceptibility in
540 *Saccharomyces cerevisiae*. *MBio* *9*, e01291-18. <https://doi.org/10.1128/mBio.01291-18>.
- 541 Bloom, J.S., Ehrenreich, I.M., Loo, W.T., Lite, T.-L.V., and Kruglyak, L. (2013). Finding the sources of
542 missing heritability in a yeast cross. *Nature* *494*, 234–237. <https://doi.org/10.1038/nature11867>.
- 543 Bloom, J.S., Boocock, J., Treusch, S., Sadhu, M.J., Day, L., Oates-Barker, H., and Kruglyak, L. (2019).
544 Rare variants contribute disproportionately to quantitative trait variation in yeast. *ELife* *8*, e49212.
545 <https://doi.org/10.7554/eLife.49212>.
- 546 Boeke, J.D., Trueheart, J., Natsoulis, G., and Fink, G.R. (1987). 5-Fluoroorotic acid as a selective agent in
547 yeast molecular genetics. *Methods Enzymol.* *154*, 164–175. [https://doi.org/10.1016/0076-6879\(87\)54076-](https://doi.org/10.1016/0076-6879(87)54076-9)
548 *9*.
- 549 Brachmann, C.B., Davies, A., Cost, G.J., Caputo, E., Li, J., Hieter, P., and Boeke, J.D. (1998). Designer
550 deletion strains derived from *Saccharomyces cerevisiae* S288C: a useful set of strains and plasmids for
551 PCR-mediated gene disruption and other applications. *Yeast Chichester Engl.* *14*, 115–132.
552 [https://doi.org/10.1002/\(SICI\)1097-0061\(19980130\)14:2<115::AID-YEA204>3.0.CO;2-2](https://doi.org/10.1002/(SICI)1097-0061(19980130)14:2<115::AID-YEA204>3.0.CO;2-2).
- 553 Bystrykh, L.V. (2012). Generalized DNA Barcode Design Based on Hamming Codes. *PLOS ONE* *7*,
554 e36852. <https://doi.org/10.1371/journal.pone.0036852>.
- 555 Cardinale, S., and Arkin, A.P. (2012). Contextualizing context for synthetic biology - identifying causes of
556 failure of synthetic biological systems. *Biotechnol. J.* *7*, 856–866. <https://doi.org/10.1002/biot.201200085>.
- 557 Cherry, J.M., Hong, E.L., Amundsen, C., Balakrishnan, R., Binkley, G., Chan, E.T., Christie, K.R.,
558 Costanzo, M.C., Dwight, S.S., Engel, S.R., et al. (2012). *Saccharomyces* Genome Database: the genomics
559 resource of budding yeast. *Nucleic Acids Res.* *40*, D700-705. <https://doi.org/10.1093/nar/gkr1029>.
- 560 Costanzo, M., VanderSluis, B., Koch, E.N., Baryshnikova, A., Pons, C., Tan, G., Wang, W., Usaj, M.,
561 Hanchard, J., Lee, S.D., et al. (2016). A global genetic interaction network maps a wiring diagram of
562 cellular function. *Science* *353*, aaf1420. <https://doi.org/10.1126/science.aaf1420>.
- 563 Costanzo, M., Hou, J., Messier, V., Nelson, J., Rahman, M., VanderSluis, B., Wang, W., Pons, C., Ross,
564 C., Ušaj, M., et al. (2021). Environmental robustness of the global yeast genetic interaction network.
565 *Science* *372*, eabf8424. <https://doi.org/10.1126/science.abf8424>.
- 566 Ehrenreich, I.M., Bloom, J., Torabi, N., Wang, X., Jia, Y., and Kruglyak, L. (2012). Genetic architecture
567 of highly complex chemical resistance traits across four yeast strains. *PLoS Genet.* *8*, e1002570.
568 <https://doi.org/10.1371/journal.pgen.1002570>.

- 569 Engel, S.R., Dietrich, F.S., Fisk, D.G., Binkley, G., Balakrishnan, R., Costanzo, M.C., Dwight, S.S., Hitz,
570 B.C., Karra, K., Nash, R.S., et al. (2014). The reference genome sequence of *Saccharomyces cerevisiae*:
571 then and now. *G3 Bethesda Md* 4, 389–398. <https://doi.org/10.1534/g3.113.008995>.
- 572 Foat, B.C., Tepper, R.G., and Bussemaker, H.J. (2008). TransfactomeDB: a resource for exploring the
573 nucleotide sequence specificity and condition-specific regulatory activity of trans-acting factors. *Nucleic
574 Acids Res.* 36, D125-131. <https://doi.org/10.1093/nar/gkm828>.
- 575 Gietz, R.D., and Schiestl, R.H. (2007). High-efficiency yeast transformation using the LiAc/SS carrier
576 DNA/PEG method. *Nat. Protoc.* 2, 31–34. <https://doi.org/10.1038/nprot.2007.13>.
- 577 Griffith, O.L., Montgomery, S.B., Bernier, B., Chu, B., Kasaian, K., Aerts, S., Mahony, S., Sleumer, M.C.,
578 Bilenky, M., Haeussler, M., et al. (2008). ORegAnno: an open-access community-driven resource for
579 regulatory annotation. *Nucleic Acids Res.* 36, D107-113. <https://doi.org/10.1093/nar/gkm967>.
- 580 Grishkevich, V., and Yanai, I. (2013). The genomic determinants of genotype × environment interactions
581 in gene expression. *Trends Genet. TIG* 29, 479–487. <https://doi.org/10.1016/j.tig.2013.05.006>.
- 582 Harbison, C.T., Gordon, D.B., Lee, T.I., Rinaldi, N.J., Macisaac, K.D., Danford, T.W., Hannett, N.M.,
583 Tagne, J.-B., Reynolds, D.B., Yoo, J., et al. (2004). Transcriptional regulatory code of a eukaryotic
584 genome. *Nature* 431, 99–104. <https://doi.org/10.1038/nature02800>.
- 585 Harris, A., Wagner, M., Du, D., Raschka, S., Nentwig, L.-M., Gohlke, H., Smits, S.H.J., Luisi, B.F., and
586 Schmitt, L. (2021). Structure and efflux mechanism of the yeast pleiotropic drug resistance transporter
587 Pdr5. *Nat. Commun.* 12, 5254. <https://doi.org/10.1038/s41467-021-25574-8>.
- 588 Hillenmeyer, M.E., Fung, E., Wildenhain, J., Pierce, S.E., Hoon, S., Lee, W., Proctor, M., St. Onge, R.P.,
589 Tyers, M., Koller, D., et al. (2008). The Chemical Genomic Portrait of Yeast: Uncovering a Phenotype for
590 All Genes. *Science* 320, 362–365. <https://doi.org/10.1126/science.1150021>.
- 591 Hu, J.H., Miller, S.M., Geurts, M.H., Tang, W., Chen, L., Sun, N., Zeina, C.M., Gao, X., Rees, H.A., Lin,
592 Z., et al. (2018). Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. *Nature*
593 556, 57–63. <https://doi.org/10.1038/nature26155>.
- 594 Jaffe, M., Dziulko, A., Smith, J.D., St Onge, R.P., Levy, S.F., and Sherlock, G. (2019). Improved
595 discovery of genetic interactions using CRISPRiSeq across multiple environments. *Genome Res.* 29, 668–
596 681. <https://doi.org/10.1101/gr.246603.118>.
- 597 Jandrositz, A., Turnowsky, F., and Högenauer, G. (1991). The gene encoding squalene epoxidase from
598 *Saccharomyces cerevisiae*: cloning and characterization. *Gene* 107, 155–160.
599 [https://doi.org/10.1016/0378-1119\(91\)90310-8](https://doi.org/10.1016/0378-1119(91)90310-8).
- 600 Jones, G.M., Stalker, J., Humphray, S., West, A., Cox, T., Rogers, J., Dunham, I., and Prelich, G. (2008).
601 A systematic library for comprehensive overexpression screens in *Saccharomyces cerevisiae*. *Nat.
602 Methods* 5, 239–241. <https://doi.org/10.1038/nmeth.1181>.
- 603 Kern, A.F., Yang, G.X., Khosla, N.M., Ang, R.M.L., Snyder, M.P., and Fraser, H.B. (2021). Divergent
604 patterns of selection on metabolite levels and gene expression. *BMC Ecol. Evol.* 21, 185.
605 <https://doi.org/10.1186/s12862-021-01915-5>.
- 606 Kim, H., Ishidate, T., Ghanta, K.S., Seth, M., Conte, D., Shirayama, M., and Mello, C.C. (2014). A co-
607 CRISPR strategy for efficient genome editing in *Caenorhabditis elegans*. *Genetics* 197, 1069–1080.
608 <https://doi.org/10.1534/genetics.114.166389>.
- 609 Koressaar, T., and Remm, M. (2007). Enhancements and modifications of primer design program Primer3.
610 *Bioinforma. Oxf. Engl.* 23, 1289–1291. <https://doi.org/10.1093/bioinformatics/btm091>.

- 611 Lee, Y.W., Gould, B.A., and Stinchcombe, J.R. (2014). Identifying the genes underlying quantitative
612 traits: a rationale for the QTN programme. *AoB PLANTS* 6, plu004.
613 <https://doi.org/10.1093/aobpla/plu004>.
- 614 Legut, M., Daniloski, Z., Xue, X., McKenzie, D., Guo, X., Wessels, H.-H., and Sanjana, N.E. (2020).
615 High-Throughput Screens of PAM-Flexible Cas9 Variants for Gene Knockout and Transcriptional
616 Modulation. *Cell Rep.* 30, 2859-2868.e5. <https://doi.org/10.1016/j.celrep.2020.02.010>.
- 617 Li, J., Li, X., Zhang, S., and Snyder, M. (2019). Gene-Environment Interaction in the Era of Precision
618 Medicine. *Cell* 177, 38–44. <https://doi.org/10.1016/j.cell.2019.03.004>.
- 619 Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for
620 RNA-seq data with DESeq2. *Genome Biol.* 15, 550. <https://doi.org/10.1186/s13059-014-0550-8>.
- 621 Lum, P.Y., Armour, C.D., Stepaniants, S.B., Cavet, G., Wolf, M.K., Butler, J.S., Hinshaw, J.C., Garnier,
622 P., Prestwich, G.D., Leonardson, A., et al. (2004). Discovering modes of action for therapeutic compounds
623 using a genome-wide screen of yeast heterozygotes. *Cell* 116, 121–137. [https://doi.org/10.1016/s0092-8674\(03\)01035-3](https://doi.org/10.1016/s0092-8674(03)01035-3).
- 625 Luzzatto, L. (2012). Sick cell anaemia and malaria. *Mediterr. J. Hematol. Infect. Dis.* 4, e2012065.
626 <https://doi.org/10.4084/MJHID.2012.065>.
- 627 Magoč, T., and Salzberg, S.L. (2011). FLASH: fast length adjustment of short reads to improve genome
628 assemblies. *Bioinforma. Oxf. Engl.* 27, 2957–2963. <https://doi.org/10.1093/bioinformatics/btr507>.
- 629 Mannhaupt, G., Schnall, R., Karpov, V., Vetter, I., and Feldmann, H. (1999). Rpn4p acts as a transcription
630 factor by binding to PACE, a nonamer box found upstream of 26S proteasomal and other genes in yeast.
631 *FEBS Lett.* 450, 27–34. [https://doi.org/10.1016/s0014-5793\(99\)00467-6](https://doi.org/10.1016/s0014-5793(99)00467-6).
- 632 Martin, M. (2011). Cutadapt removes adapter sequences from high-throughput sequencing reads.
633 *EMBnet.Journal* 17, 10–12. <https://doi.org/10.14806/ej.17.1.200>.
- 634 Nguyen Ba, A.N., Lawrence, K.R., Rego-Costa, A., Gopalakrishnan, S., Temko, D., Michor, F., and Desai,
635 M.M. (2022). Barcoded bulk QTL mapping reveals highly polygenic and epistatic architecture of complex
636 traits in yeast. *ELife* 11, e73983. <https://doi.org/10.7554/eLife.73983>.
- 637 Nishimasu, H., Shi, X., Ishiguro, S., Gao, L., Hirano, S., Okazaki, S., Noda, T., Abudayyeh, O.O.,
638 Gootenberg, J.S., Mori, H., et al. (2018). Engineered CRISPR-Cas9 nuclease with expanded targeting
639 space. *Science* 361, 1259–1262. <https://doi.org/10.1126/science.aas9129>.
- 640 Pachkov, M., Balwierz, P.J., Arnold, P., Ozonov, E., and van Nimwegen, E. (2013). SwissRegulon, a
641 database of genome-wide annotations of regulatory sites: recent updates. *Nucleic Acids Res.* 41, D214-
642 220. <https://doi.org/10.1093/nar/gks1145>.
- 643 Peter, J., De Chiara, M., Friedrich, A., Yue, J.-X., Pflieger, D., Bergström, A., Sigwalt, A., Barre, B.,
644 Freel, K., Llored, A., et al. (2018). Genome evolution across 1,011 *Saccharomyces cerevisiae* isolates.
645 *Nature* 556, 339–344. <https://doi.org/10.1038/s41586-018-0030-5>.
- 646 Reinke, A., Chen, J.C.-Y., Aronova, S., and Powers, T. (2006). Caffeine targets TOR complex I and
647 provides evidence for a regulatory link between the FRB and kinase domains of Tor1p. *J. Biol. Chem.* 281,
648 31616–31626. <https://doi.org/10.1074/jbc.M603107200>.
- 649 Riccitelli, N.J., Delwart, E., and Lupták, A. (2014). Identification of minimal HDV-like ribozymes with
650 unique divalent metal ion dependence in the human microbiome. *Biochemistry* 53, 1616–1626.
651 <https://doi.org/10.1021/bi401717w>.
- 652 Richardson, C.D., Ray, G.J., DeWitt, M.A., Curie, G.L., and Corn, J.E. (2016). Enhancing homology-
653 directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA.
654 *Nat. Biotechnol.* 34, 339–344. <https://doi.org/10.1038/nbt.3481>.

655 Rine, J., Hansen, W., Hardeman, E., and Davis, R.W. (1983). Targeted selection of recombinant clones
656 through gene dosage effects. *Proc. Natl. Acad. Sci. U. S. A.* *80*, 6750–6754.
657 <https://doi.org/10.1073/pnas.80.22.6750>.

658 Rockman, M.V. (2012). The QTN program and the alleles that matter for evolution: all that’s gold does
659 not glitter. *Evol. Int. J. Org. Evol.* *66*, 1–17. <https://doi.org/10.1111/j.1558-5646.2011.01486.x>.

660 Rodrigues, M.L. (2018). The Multifunctional Fungal Ergosterol. *MBio* *9*, e01755-18.
661 <https://doi.org/10.1128/mBio.01755-18>.

662 Sharon, E., Chen, S.-A.A., Khosla, N.M., Smith, J.D., Pritchard, J.K., and Fraser, H.B. (2018). Functional
663 Genetic Variants Revealed by Massively Parallel Precise Genome Editing. *Cell* *175*, 544-557.e16.
664 <https://doi.org/10.1016/j.cell.2018.08.057>.

665 She, R., and Jarosz, D.F. (2018). Mapping Causal Variants with Single-Nucleotide Resolution Reveals
666 Biochemical Drivers of Phenotypic Change. *Cell* *172*, 478-490.e15.
667 <https://doi.org/10.1016/j.cell.2017.12.015>.

668 Smith, E.N., and Kruglyak, L. (2008). Gene-environment interaction in yeast gene expression. *PLoS Biol.*
669 *6*, e83. <https://doi.org/10.1371/journal.pbio.0060083>.

670 Steinmetz, L.M., Sinha, H., Richards, D.R., Spiegelman, J.I., Oefner, P.J., McCusker, J.H., and Davis,
671 R.W. (2002). Dissecting the architecture of a quantitative trait locus in yeast. *Nature* *416*, 326–330.
672 <https://doi.org/10.1038/416326a>.

673 Tishkoff, S.A., Reed, F.A., Ranciaro, A., Voight, B.F., Babbitt, C.C., Silverman, J.S., Powell, K.,
674 Mortensen, H.M., Hirbo, J.B., Osman, M., et al. (2007). Convergent adaptation of human lactase
675 persistence in Africa and Europe. *Nat. Genet.* *39*, 31–40. <https://doi.org/10.1038/ng1946>.

676 Via, S., and Lande, R. (1985). GENOTYPE-ENVIRONMENT INTERACTION AND THE EVOLUTION
677 OF PHENOTYPIC PLASTICITY. *Evolution* *39*, 505–522. <https://doi.org/10.1111/j.1558-5646.1985.tb00391.x>.

678


679 Yang, M., Jensen, L.T., Gardner, A.J., and Culotta, V.C. (2005). Manganese toxicity and *Saccharomyces*
680 *cerevisiae* Mam3p, a member of the ACDP (ancient conserved domain protein) family. *Biochem. J.* *386*,
681 479–487. <https://doi.org/10.1042/BJ20041582>.

682 Zhao, B., Chen, S.-A.A., Lee, J., and Fraser, H.B. (2022). Bacterial Retrons Enable Precise Gene Editing
683 in Human Cells. *CRISPR J.* *5*, 31–39. <https://doi.org/10.1089/crispr.2021.0065>.

684

685

686 **Main figures**



688 **Figure 1: Design and validation of CRISPEY-BAR for generating and tracking**
689 **thousands of precise genome edits simultaneously.**

690

691 *a*, Schematic of CRISPEY-BAR dual edit strategy.

692 Top, CRISPEY-BAR expression cassette consisting of pGAL7 galactose-inducible
693 promoter and terminator (brown); self-cleaving HDV-like-ribozymes RzCIV, RZHDV and
694 RZSpur3 (magenta); barcode insertion retron-guide cassette (blue) containing
695 programmed barcode (orange) and UMI (yellow); variant editing cassette (green).

696 Middle, the variant editing cassette converts a wildtype (WT) allele into an alternative
697 allele. Bottom, the barcode insertion retron-guide cassette

698

699 *b*, Schematic for conventional CRISPEY. Variants tracked across three growth replicates
700 by plasmids containing guide-donor oligo.

701

702 *c*, Schematic for CRISPEY-BAR. Variants tracked across three growth replicates by
703 genomically-integrated barcodes with attached UMIs.

704

705 *d*, Workflow for CRISPEY-BAR library pool construction.

706

707 *e*, Validation of genomic variant editing rate from CRISPEY-BAR.

708 Blue, randomly picked colonies that contain both genomic-integrated barcode and the
709 designed edit. Orange, randomly picked colonies that contain only the genomic-
710 integrated barcode but not the designed edit.

711

712 *f*, Schematic for CRISPEY-BAR pooled competition in yeast.

713

714 *g*, Example of CRISPEY-BAR data over time.

715 Each line indicates normalized counts for a single UMI for a given barcode from 1 of 3
716 replicates in a competition experiment. Counts in later time points are normalized to the
717 first time point. Light blue and blue: two barcodes representing different guides targeting
718 the same variant chr7: 848783 AC>A. Red and dark red: two barcodes representing

719 different guides targeting the same variant chr7: 847050 C>A. Gray scale: Non-targeting
720 of variants, barcode integration only (no-edit control regarding variants). Data shown are
721 from Terbinafine competition across approximately 26 generations.

722

723 *h*, Example of outlier removal. Green solid line, normalized reads from an outlier UMI.
724 Green dotted line, normalized sum of reads from all UMIs of the barcode. Gray solid line,
725 normalized reads from non-outlier UMIs. Black dotted line, normalized sum of reads from
726 all UMIs of the barcode excluding outlier UMI.

727


728 *i*, Replication of fitness effects between two competition triplicates in synthetic complete
729 media (SC). Orange, variants with FDR < 0.25 in both triplicates. Blue, variants with FDR
730 ≥ 0.25 in one or more triplicates.

731

732 *j*, Replication of fitness effects. X-axis and Y-axis indicate fitness effects measured by
733 two independent CRISPEY-BAR experiments, pool#1 and pool#4, in cobalt chloride. Or-
734 ange, variants with FDR < 0.25 in pool#1. Blue, variants with FDR ≥ 0.25 in pool#1.

735

736 *k*, Validation of pooled fitness in fluconazole by pairwise competition. X-axis, fitness ef-
737 fect measured by CRISPEY-BAR pooled competition. Y-axis, fitness effect measured
738 through pairwise competition against GFP strain using flow cytometry. Data shown for 13
739 variants in fluconazole. Data presented as mean \pm SEM.



741 **Figure 2: Detection of natural variants affecting fitness within QTLs mapped in**
742 **complex traits.**

743

744 a, Diagram of library design process showing the selection of QTLs from three different
745 conditions, sourcing of natural variants, as well as library statistics.

746

747 b, Schematic for experiment workflow for QTL region variant fitness mapping with
748 CRISPEY-BAR.

749

750 c, Number of variants with fitness effect ($FDR < 0.01$) within SC and appropriate stress
751 condition.

752

753 d, Annotation enrichment of variants with fitness effect ($FDR < 0.01$). Blue, variant
754 enrichment for hits in fluconazole condition. Orange, variant enrichment for hits in
755 caffeine condition. Green, variant enrichment for hits in cobalt chloride condition.

756


757 e, Fitness effects of example QTL regions. Dark blue, fitness effects in stress condition
758 ($FDR < 0.01$). Dark orange, fitness effects in SC ($FDR < 0.01$). Light blue, no fitness
759 effects stress condition. Gold, no fitness effects in SC. Most variants are represented
760 twice (effect in QTL condition and complete media).

761

762 f, *PDR5* fitness effects in CAFF and FLC. Magenta, *PDR5* variant fitness measured in
763 caffeine condition. Orange, *PDR5* variant fitness measured in fluconazole condition.
764 Dark gray, noncoding regions flanking *PDR5*. Light gray, coding region of *PDR5*. Vertical
765 lines connect the same variant fitness values measured in both caffeine and fluconazole.

766

767 g, Diagram depicting primary ecological origins of two adjacent variants mutating K940 in
768 *PDR5* with significant fitness effects.



769

770 **Figure 3: CRISPEY-BAR enabled robust mapping of variant-level GxE interactions**
 771 **within the ergosterol biosynthesis pathway**

772

773 a, Ergosterol pathway diagram showing 25 genes from the ergosterol synthesis pathway
 774 surveyed in this study. Lovastatin and terbinafine target genes in the ergosterol pathway,
 775 indicated by magenta inhibition lines.

776

777 b, The same pool of yeast edited at natural ergosterol pathway variants was grown in six
 778 different conditions and tracked by barcode sequencing.

779

780 c, Gene level fitness effects of surveyed natural variants in six conditions. X-axis labels
781 indicate the genes containing the variants. Red, variants with fitness effects (FDR <
782 0.01). Gray, non-significant variants. Target genes are outlined by dashed black lines
783 where applicable for a given condition.

784

785 d, GxE interactions were calculated between each pair of conditions (15 pairwise
786 comparisons).

787

788 e, Diagram showing definition of GxE variants in this study: A positive effect variant
789 (black circle) in condition 1 can either have the same effect in another condition (white
790 circle at same height in red region), a stronger positive effect (top white circle in red
791 region), no effect, white circle at zero, or a negative effect (bottom white circle in blue
792 region). If the variant has a negative effect or no effect at all in condition 2 (blue and light
793 blue regions), it is labeled as GxE.

794

795 f, The number of significant GxE interactions for each pairwise comparison.


796

797 g, GxE annotation enrichments for variants with GxE. Enrichment of variants with GxE in
798 each category were normalized to all variants tested. Red dashed line indicates an
799 enrichment factor of 1.0, corresponding to no enrichment over the library.

800

801 h, Variants with GxE effects within the *HMG1* promoter. Clusters of variants with
802 significant GxE effects within 8 bp of each other are in gray highlighted areas. Beginning
803 of the *HMG1* gene body is shown as a blue rectangle. Green, variants fitness effect in
804 caffeine (CAFF) condition. Purple, variant fitness effect in lovastatin (LOV) condition.

805



806

807 **Figure 4: Quantifying GxE interactions among ergosterol pathway variants**

808

809 a, Schematic of rare GxE between conditions (correlated effects).

810

811 b, Schematic of common GxE between conditions (uncorrelated effects).

812

813 c, Fitness effects of variants within *PDR5* in caffeine and fluconazole.

814


815 d, Fitness effects of variants within ergosterol pool in lovastatin and CoCl₂.

816

817 e, Histogram showing the fraction of variants with significant fitness effects within a pair
818 of conditions which show non-magnitude GxE for the ergosterol pool. *PDR5* variants
819 measured in caffeine and fluconazole are shown as a dotted gray line.

820

821 f, Heatmaps showing fitness effects of all variants with a significant effect in any
822 condition. Significant positive effects (red), significant negative effects (blue), non-
823 significant positive effects (pink), and non-significant negative effects (light blue). Far
824 right column indicates variant with at least one GxE interaction (green) and without GxE
825 (grey).



826

827 **Figure 5: Types of GxE variants and effect of natural variation on *ERG4***

828 **expression.**

829

830 a, Example of fitness effect detected in only one condition.

831

832 *b*, Example of fitness effects with same direction detected in two conditions.

833

834 *c*, Example of fitness effects with opposite directions between conditions, showing sign
835 GxE.

836

837 *d*, Sign GxE variants have larger maximum fitness effects. Whiskers represent Q3 +
838 1.5xIQR and Q1 - 1.5xIQR, or the maximum and minimum values of the dataset if these are
839 respectively lower or higher than the IQR based intervals.


840

841 *e*, Effect of natural variants on *ERG4* expression. Top left: Consensus Rpn4p binding
842 motif. Top right: Genomic location of Rpn4p binding site affected by chr7: 472522 C>A
843 variant within *ERG4/PDR1* divergent promoter. Bottom left: Variants of Rpn4p binding
844 site within *ERG4/PDR1* promoter tested. Bottom right: qRT-PCR measured expression
845 of *ERG4* scaled by wildtype expression in an unedited strain, data presented as mean ±
846 SEM.

847

848


849 Supplemental figures



850

851 **Supplemental Figure S1: Schematic for library cloning in CRISPEY-BAR.** Pooled
852 oligonucleotide libraries, empty vector sequence (pSAC200) and an example of ligated
853 *ADE2* editing vector (pSAC212) can be found in Supplementary Table S1.

854




855

856


857 **Supplemental Figure S2: Schematic for pooled editing and growth competition in**
 858 **CRISPEY-BAR. STAR Methods** for detailed description.

859



860

861 **Supplemental Figure S3: Schematic for CRISPEY-BAR sequencing library**
 862 **preparation.** Primer sequences can be found in Supplementary table S1.




863


864 **Supplemental Figure S4: Clustering analysis for different variant types.**

865 a, Promoter variant clustering. b, Downstream variant clustering.

866 c, Synonymous variant clustering. d, Missense variant clustering.




867
868 **Supplemental Figure S5: Overlap between variants with effects on fitness and GxE**
869 **variants at differing FDR thresholds.** Line indicates measured overlap at FDR < 0.01
870 for both thresholds for variants measured in all six conditions.
871



872
873 **Supplemental Figure S6: Fraction of variants with fitness effects harboring GxE is**
874 **not dependent upon specific conditions analyzed.** Each dot indicates fraction of
875 variants with fitness effects harboring GxE across conditions analyzed, where the

876 conditions are subsets of the 6 conditions in **Figure 3d**. Dashed line indicates fraction of
877 GxE across all six conditions.

878



879

880

881 **Supplemental Figure S7: Fitness and *ERG4* expression for variants in Figure 5e.**

882 X-axis: Paired fitness from flow cytometry measurements similar to **Figure 1i**, see also **STAR**

883 **Methods**. Y-axis: *ERG4* expression change same as shown in **Figure 5e**. Data presented as

884 mean ± SEM.

885 **STAR ★ Methods**

886 **Contact for Reagent and Resource Sharing**

887 Further information and requests for reagents may be directed to and will be fulfilled by
888 the corresponding author Hunter Fraser (hbfraser@stanford.edu).

889

890 **Experimental Model and Subject Details**

891 All strains used in this study were derivatives of *S. cerevisiae* BY4742 (Brachmann et al.,
892 1998). Construction of strains with integrated SpCas9 and Ec86 Reverse Transcriptase
893 was described previously (Sharon et al., 2018).

894

895 **Method details**

896 **Variant selection and pooled oligonucleotide design**

897 Natural variants were sourced from the 1,011 genomes project documented the following
898 criteria (Peter et al., 2018). For QTL fine mapping, QTLs (Bloom *et al.*, 2019
899 supplementary file [elife-49212-Figure3-data1-v2.xls](#), sheet_name='within-cross model')
900 were filtered for QTLs containing only one gene, have a q-value > 0.05, then ranked by
901 Beta_abs for maximum effect size (Bloom et al., 2019). We excluded the following genes
902 to avoid interference with CRISPEY editing and genes unavailable from the base strain
903 genotype: HO, HIS3, URA3, LEU2, LYS2, GAL1, GAL3, GAL4, GAL7, GAL10, GAL80,
904 HAP1 and POLR2. The QTL borders were defined by coordinates within '1.5 LOD drop
905 CI, left' and '1.5 LOD drop CI, right' as annotated in Bloom, 2019, and gene regions were
906 defined by +/-500bp from the coding region (Bloom et al., 2019). Natural variants within
907 the union of the QTL borders and the gene region were included in the library
908 corresponding to the traits, excluding singletons and doubletons (Peter et al., 2018). The
909 traits include growth in: 'Cobalt_Chloride;2mM;2', 'Caffeine;15mM;2' and
910 'Fluconazole;100uM;2', and we refer to these traits as 'stress conditions' (Bloom et al.,

911 2019). For the ergosterol pool, all non-reference alleles from yeast natural variants that
912 were within +/-500bp from the coding region of the selected ergosterol pathway genes
913 were included⁴. We targeted more than 1000 variants per QTL condition pool, and all
914 possible variants for the ergosterol pool (**Figure 2a,3a**). We designed CRISPEY oligos to
915 edit these variants in the ZRS111 strain, which contains the S288c reference alleles. The
916 guides and donors selected for CRISPEY editing were designed as described, with the
917 following parameters or modifications (Sharon et al., 2018): 1. The alternative allele is
918 within -6 to -1 and +1 to +2 positions of the guide target and PAM sequences; 2. The
919 donor template is 108 bp in length with asymmetric homology arms, 40 bp for the 5' arm
920 and 68 bp for the 3' arm; 3. Variants were included if two or more guides were found for
921 a given variant. The resulting msDNA donor will result in a shorter 3' homology arm and
922 longer 5' arm flanking the variant, which was to have higher HDR efficiency using ssDNA
923 as repair donor (Richardson et al., 2016). The donors were further filtered to exclude
924 SphI, Ascl and NotI restriction sites used in the cloning process, as well as keeping a
925 minimum of 30 bp homology arm 5' of variant and 55 bp 3' of homology arm in the donor
926 template. The resulting output is 250 bp per oligo, consists of 5' homology to the
927 pSAC200 CRISPEY-BAR vector, 12 bp programmed barcode, restriction site region for
928 cloning, 108 bp donor template sequence, 34 bp constant region, 20 bp guide sequence
929 and 3' homology to the pSAC200 CRISPEY-BAR vector (**Supplemental Figure 1**).

930 Specifically, the general sequence is: 5'-

931 GTTG CAGTTAGCTAACAGGCCATGCNNNNNNNNNNNNNGCATGCAGCGGCCGCAGG
932 CGCGCCNN
933 NNN
934 NNNNNNAGGAAACCCGTTTCTTCTGACGTAAGGGTGCGCANNNNNNNNNNNNNNNNNNNN
935 NNNNNGTTTCAGAGCTATGCTGGAAACAGCAT-3', where the first 12 Ns represent
936 programmed barcodes, the following 108 Ns represent donor template sequence, and
937 the last 20 Ns represent guide sequence.

938

939 **Programmed Barcode Design**

940 Barcodes were designed using a custom script implementing a quaternary
941 Hamming(12,8) code based on the encoding scheme described in a previous study

942 (Bystrykh, 2012). This encoding scheme generates DNA barcodes with a minimum
943 Hamming distance of 3, allowing for error correction of 1 bp mutations or DNA
944 sequencing errors. The list of all Hamming(12,8) DNA barcodes was then filtered to
945 remove barcodes containing restriction sites used in our cloning process, Illumina i5 and
946 i7 Nextera handles, homonucleotide stretches greater than length 3, dinucleotide repeats
947 greater than length 5, any 12 bp section of pSAC200, and any 12 bp section of our
948 custom sequencing primers. In addition, Primer3 was used to predict any hairpin
949 structures, and if a structure was found, that barcode was removed (Koressaar and
950 Remm, 2007). The final list of barcodes was then assigned to 392 possible wells,
951 ensuring that barcodes within each well had a minimum Hamming distance of 5,
952 theoretically enabling error correction of sequencing errors in up to 2 bp for barcodes
953 within the same well.

954

955 **Library cloning**

956 Primers and additional oligonucleotides can be found in **Supplemental Table S1**.
957 Oligonucleotide (Twist Biosciences) libraries were ordered in the format of 192 wells,
958 each well containing 121 oligonucleotides each. This format allows pooling of
959 oligonucleotides in combinations relevant to each competition experiment. Each well
960 included 119 variant editing oligonucleotides, 1 control oligonucleotide with a non-editing
961 guide (sgGFP) and 1 control oligonucleotide editing a 8-bp frameshift deletion as a
962 positive control with gene knockout effects adapted from a previous study (Bao et al.,
963 2018).

964 Oligonucleotides were first amplified with Q5 polymerase (NEB) with 1 μ M primer #615
965 and #576 in 50 μ L reaction following manufacturer instructions and initial denaturation of
966 98°C for 2 min, and then 5 cycles of 98°C for 10 s and 65°C for 30 s, followed by 25
967 cycles of 98°C for 10 s and 69°C for 40 s, then final extension of 72°C for 2 min. PCR
968 products were then purified with 45 μ L nucleoMAG NGS beads (hereafter, “beads”)
969 (Takara) and eluted with 20 μ L water. 2 μ L of the first round PCR product was further
970 amplified with Q5 polymerase (NEB) with 1 μ M primer #615 and #576 in 50 μ L reaction
971 as manufacturer instructions and initial denaturation of 98°C for 2 min, and then 15
972 cycles of 98°C for 10 s and 69°C for 30 s, then final extension of 72°C for 2 min. Second

973 round PCR products were then purified with 45 uL beads and eluted with 20 uL Tris pH
974 8.0. We quantified and pooled PCR products from each well by equal volume to the
975 assigned pools (**Supplemental Table S2**).

976 The pooled oligonucleotides PCR products were purified using SizeSelect II 2% gel
977 (Invitrogen), followed by bead purification and prepared NGS libraries to quantify the
978 counts from each well. Briefly, the pooled oligos were amplified with Q5 polymerase
979 (NEB) with 1 uM primer #617 and #337-343 in 50 uL reaction following manufacturer
980 instructions and initial denaturation of 98°C for 2 min, and then 15 cycles of 98°C for 10 s
981 and 69°C for 40 s, then final extension of 72°C for 2 min, followed by purification using
982 45 uL beads and indexing PCR using Illumina dual-indexing primers. The indexed
983 amplicons corresponding to each pool were then sequenced by MiSeq using reagent kit
984 v2 Nano to obtain paired-end 150bp reads that are mapped to the designed
985 oligonucleotides. We counted the relative proportions of oligonucleotides from each well
986 in the assigned pool, then re-pooled the PCR products again with normalized volumes to
987 target equal molarity between wells in each pool.

988 The pSAC200 empty vector was digested twice with NotI-HF (NEB) and Quick CIP
989 (NEB), and the linearized vector was purified using beads. 290 ng of linearized pSAC200
990 vector and 140 ng of well-normalized, pooled oligonucleotide PCR products from above
991 were assembled in 20 uL NEBuilder HiFi mastermix (NEB) reaction according to
992 manufacturer instructions, with 1:10 molar ratio between vector:insert. The assembled
993 products were purified by beads and eluted in 10 uL water. 3 uL of the assembled
994 products were used for electroporation with 27 uL Endura Electrocompetent cells for
995 CRISPR DUO (Lucigen). Two electroporation reactions were performed for each pool
996 following manufacturer instructions and recovered in SOC media (Lucigen) for 25 min at
997 37°C and plated to a single 15 cm LB agar plate with Carbenicillin (GoldBio). A serial
998 dilution of the recovered bacteria was plated to estimate colony forming units (cfu), and all
999 pools contained more than 500,000 cfus. The transformants were incubated for 22 hr at
1000 32°C and the resulting bacterial lawn was collected for storage in LB with 10% glycerol at
1001 -80°C. Half of the collected transformant stock was used for plasmid extraction using
1002 Nucleobond Xtra Midi Plus (Macherey-Nagel) and eluted as “post-Gibson” plasmid pools,
1003 yielding 105-120 ug of plasmid DNA.

1004 20 ug of post-Gibson plasmid pools were digested twice with SphI-HF(NEB), Ascl(NEB),
1005 Quick-CIP(NEB) and NotI-HF (NEB), purified by beads and eluted in 12 uL 10mM Tris
1006 8.0 as ligation vectors. A mixture of six UMI associated ligation inserts was generated by
1007 six 100 uL reactions Q5 (NEB) PCR reaction with one of six forward primers: #591,
1008 #592, #594, #506, #603 and #604; and reverse primer #590, with plasmid pSAC212 as
1009 template. PCR was performed with 1 uM of each primer as manufacturer instructions,
1010 and initial denaturation of 98°C for 3 min, and then 35 cycles of 98°C for 10 s, 66°C for
1011 30 s, 72°C for 40 s; then final extension of 72°C for 2 min. The ligation insert PCR
1012 products were digested with SphI-HF (NEB) and Ascl (NEB) and bead purified, then
1013 pooled in equal molar into a mixture of six UMI ligation inserts. 1 ug of the linearized pool
1014 vectors were ligated to 1.5 ug of six UMI ligation mix (vector:insert=1:30) with 10 uL T4
1015 ligase (NEB) in 100 uL 1x T4 ligase buffer at 16°C overnight.
1016 The ligation product was purified by beads and eluted in 30 uL water. 3 uL of the purified
1017 ligation products were used for electroporation with 27 uL Endura Electrocompetent cells
1018 for CRISPR DUO (Lucigen). Two electroporation reactions were performed for each
1019 pool, one reaction with ligation insert and the other without insert as negative control.
1020 Electroporation was performed following manufacturer instructions and recovered in
1021 SOC media (Lucigen) for 30 min at 37°C and the with-insert ligations were plated to two
1022 15 cm LB agar plates with Carbenicillin (GoldBio) at 32°C for 22 hr. A serial dilution of
1023 the recovered bacteria from both with- and without-insert ligations was plated to estimate
1024 cfu, and all pools contained more than 1,000,000 cfu, corresponding to at least 2,500x
1025 coverage for each oligonucleotide on average within each pool. Ligation plates were
1026 incubated at 32°C for 22 hr, and transformants were stored in LB with 10% glycerol.
1027 Ligated plasmids were extracted from one fourth of the collected bacteria from each pool
1028 using Nucleobond Xtra Midi Plus (Macherey-Nagel) and eluted as “post-ligation” plasmid
1029 pools, yielding 160-240 ug of plasmid DNA per reaction.

1030

1031 **Yeast transformation, editing induction and plasmid curing**

1032 The base strain ZRS111 was described previously(Sharon et al., 2018). 4 ug of the post-
1033 ligation plasmid pools were digested with NotI-HF (NEB) and quick-CIP(NEB) and
1034 directly transformed into the yeast strain ZRS111 by LiOAc heat shock transformation

1035 (Gietz and Schiestl, 2007). The yeast transformant pools were selected on YNB -
1036 histidine -uracil 2% glucose (1.7g/L yeast nitrogen base (RPI); 5 g/L Ammonium Sulfate
1037 (ACROS organics); 1.9 g Dropout synthetic mix minus histidine, uracil w/o nitrogen base
1038 (US Biological) and 20 g/L glucose (Sigma) 2% agar plates and stored in YNB -histidine -
1039 uracil 2% glucose media with 15% glycerol at -80°C. Yeast transformants containing
1040 post-ligation pools were inoculated to 200 mL YNB -histidine -uracil 2% raffinose (1.7 g/L
1041 yeast nitrogen base (RPI); 5 g/L Ammonium Sulfate (ACROS organics); 1.9 g Dropout
1042 synthetic mix minus histidine, uracil w/o nitrogen base (US Biological) and 20 g/L
1043 raffinose (Sigma) media starting at OD₆₀₀=0.4, shaking at 30°C for 16 hr (**Supplemental**
1044 **Figure S2**). The raffinose cultures were further re-inoculated in 200 mL YNB -histidine -
1045 uracil 2% galactose media starting at OD₆₀₀=0.4 and shaking at 30°C for 24 hr three
1046 times, for a total of 72 hr in galactose media in order to induce CRISPEY-BAR editing.
1047 Cells were harvested from the last galactose media growth and stored in YNB -histidine -
1048 uracil 2% glucose media with 15% glycerol at -80°C. Edited cells were then plasmid-
1049 cured by growing in 200 mL YNB 2% glucose (1.7g/L yeast nitrogen base (RPI); 5 g/L
1050 Ammonium Sulfate (ACROS organics); 1.9 g Dropout synthetic mix complete, w/o
1051 nitrogen base (US Biological) and 20g/L glucose (Sigma) media starting at OD₆₀₀=0.4,
1052 shaking at 30°C for 16 hr, then re-inoculated to YNB 2% glucose media with 1 g/L 5-
1053 Fluororotic acid monohydrate (GoldBio) starting at OD₆₀₀=0.4, and shaking at 30°C for
1054 24 hr(Boeke et al., 1987). The plasmid-cured cells were collected and stored in YNB 2%
1055 glucose media with 15% glycerol at -80°C.

1056

1057 **Pooled competition**

1058 Pooled competitions were carried out in 1 L baffled flasks in YNB 2% glucose (SC,
1059 hereafter) media with or without specified conditions (**Supplemental Figure S2**). For
1060 stress conditions, we used the following final concentrations in SC for the stress
1061 reagents: sodium chloride (0.8M); fluconazole (7.5 ug/mL); cobalt chloride (1.5 mM);
1062 terbinafine (40 ug/mL); lovastatin (30 ug/mL, stock solution was dissolved in 15%(v/v)
1063 ethanol followed by heat activation); caffeine (1 mg/mL). The concentration of each
1064 drug/salt was titrated to approximately 5 generations of growth of the ZRS111 strain
1065 every 12 hr, indicating overall decreased fitness in each condition to apply consistent

1066 growth stress to cells. In contrast, for SC media only, there are approximately 5
1067 generations of growth ZRS111 strain in 8 hr. Cells were thawed in 200 mL SC media
1068 from glycerol stock starting at OD₆₀₀=0.4 and grown at 30°C shaking at 250 RPM. Cells
1069 were passaged every 12 hr and diluted to fresh 1 mL SC media with specified conditions,
1070 and every 8 hr for SC media only. Five intervals separated by six timepoints (T1~T6)
1071 were harvested at every time point once passage was complete. Harvested cells were
1072 spun down, washed with water, and stored at -20°C.

1073

1074 **Sequencing library preparation**

1075 Yeast genomic DNA was extracted from 60 - 80 OD of each sample using the
1076 MasterPure Yeast DNA Purification Kit (Lucigen) with four reactions per sample.
1077 Genomic DNA was eluted in 200 uL per sample, further digested with 1 uL RNaseA and
1078 quantified by Qubit dsDNA HS assay (Invitrogen). 10 ug of genomic DNA was amplified
1079 in 400 uL Q5 polymerase (NEB) PCR reaction with 1 uM forward primer #261 and 1 uM
1080 reverse primer equimolar mix of primers #327~#334 (**Supplemental Figure S3**). PCR
1081 was performed following manufacturer's instructions, with 1M Betaine and initial
1082 denaturation of 98°C for 2 min, then 19 cycles of 98°C for 10 s, 65°C for 20 s; then
1083 extension at 72°C for 5 min. 100 uL of first round of PCR products were purified using
1084 100 uL beads and 15 uL of the purified amplicons were further indexed by 50 uL Q5
1085 polymerase (NEB) PCR reaction following manufacturer's instructions with 1 uM
1086 equimolar mix of indexing primers for Illumina sequencing, and initial denaturation of
1087 98°C for 2 min, then 8 cycles of 98°C for 10 s, 70°C for 20 s; then extension at 72°C for
1088 2 min. The indexed amplicons were purified with 50 uL beads, eluted in 100 uL water
1089 and quantified by Qubit dsDNA HS assay (Invitrogen). The purified, indexed amplicons
1090 from six time point samples for the three replicates per competition were mixed
1091 equimolar and purified by SizeSelect II gel (Invitrogen) for ~300 bp product. The size
1092 selected libraries were then purified by beads and submitted for paired-end sequencing
1093 on NextSeq 550 using custom read1 primer #354, with custom cycles of 12 cycles for
1094 read1, 8 + 8 cycles for dual indices and 64 cycles for read2 using a 1 x 75 bp High-
1095 Output Kit (**Supplemental Figure S3**).

1096

1097 **Read Processing**

1098 Reads in fastq format from competition libraries sequenced using NextSeq were
1099 processed using a custom script. Briefly, fastq files from the same samples were
1100 combined and adaptors were trimmed using cutadapt (Martin, 2011). Parameters for
1101 read 2 trimming were 5' adaptor sequence as 'GGCCAGTTTAAACTT', 3' adaptor
1102 sequence as 'GCATGGC', maximum error rate of 0.2 and 27 base pair in length for
1103 trimmed read2. Trimmed paired reads were merged using FLASH with minimum overlap
1104 of 12 base pairs and maximum mismatch rate of 0.25 (Magoč and Salzberg, 2011). The
1105 resulting barcode is 27 base pairs including 12 bp barcode, 6 bp SphI restriction site and
1106 9 bp UMIs. The barcode-UMI combinations with perfect match to all possible barcode-
1107 UMI combinations from the designed libraries were counted for analysis described
1108 below.

1109

1110 **Fitness calculation**

1111 Processed counts from each competition experiment of barcode-UMI combinations were
1112 combined with generation time estimated from optical density at each timepoint during
1113 fitness competition to calculate fold-change values using DESeq2 (Love et al., 2014). A
1114 minimum filter of 500 reads across 18 samples, including six time points in three
1115 replicates, was set for each barcode-UMI combination. The editing effect of each
1116 barcode-UMI combination was modeled as described previously by estimating the effect
1117 of generation time on the log fraction of barcode-UMI counts, with the Deseq2 design
1118 formula as follows (Sharon et al., 2018):

1119 $\text{Counts} \sim \text{Generation} + \text{Flask}$

1120 Where “Counts” represent read counts of each barcode-UMI combination; “Generation”
1121 represents the number of generations from the start of the growth competition, estimated
1122 by optical density as described above; “Flask” indicate the flask replicate from which the
1123 sample originated. Log₂ fold-change was estimated for counts per UMI across
1124 generation time for each barcode-UMI combination by Deseq2 (Love et al., 2014).

1125

1126 **Outlier removal and GxE fitness modeling**

1127 Individual UMI log₂ fold changes (logFC) for the same variants were combined to
1128 estimate the variant fitness effect through a weighted least squares model using a
1129 custom Python script (modified from Ang *et al*, in submission). For each genomic editing
1130 guide-donor pair with associated barcode, we removed outlier barcode-UMIs with large
1131 median absolute deviations (MAD) from the median logFC for that barcode (logFC >3.5 x
1132 MAD from median logFC for that barcode), as each barcode-UMI should reflect the same
1133 fitness effect of the genomic edit. This was intended to remove barcode-UMIs which
1134 were in strains which had acquired off-target mutations during transformation, editing or
1135 growth, particularly strong beneficial de novo mutations which would otherwise skew
1136 fitness measurements. Next, for the ergosterol library we calculated the standard
1137 deviation of the logFC of the barcode-UMIs for each programmed barcode and removed
1138 programmed barcodes with logFC standard deviation greater than or equal .05, to
1139 remove highly variable barcodes not accounted for in the previous outlier detection step.
1140 We omitted this step for the QTL pools due to higher variance that was expected among
1141 very high effect variants in those pools. We then calculated inverse-variance weights for
1142 each barcode-UMI based on its read depth across the competition by fitting a regression
1143 model fitness standard deviation ~ baseMean to the neutral UMIs at different read
1144 depths. This led to barcode-UMIs with more reads being weighted more highly, reflecting
1145 the higher confidence of their fitness effect measurements. Using Deseq2 variance
1146 directly gave inaccurately low estimates of variance. Genetic variant fitness effects
1147 across all competitions were then fit into a weighted least squares model using the
1148 weights mentioned above. The dependent variable was barcode-UMI logFC as
1149 measured by Deseq2, and the independent variables were the variant, the condition for
1150 the competition, and the interaction term between the variant and condition:

1151 $\text{logFC} \sim \text{variant} + \text{condition} + \text{variant:condition}$

1152 The variant and condition terms were categorical variables (as was the variant:condition
1153 term), reflecting the variant the UMIs are linked to, and the growth competition the logFC
1154 values came from. The variant fitness in any given condition thus reflects the difference
1155 between the neutral barcode-UMIs in that condition and the variant-linked barcode-UMIs,
1156 weighted by the read depth of each UMI. Significance is determined by a weighted t-test,

1157 and p-values were adjusted for multiple testing using the Benjamini-Hochberg procedure
1158 and significant fitness effects were controlled at FDR = 0.01 (Benjamini and Hochberg,
1159 1995).

1160 **Fluconazole Ecological Enrichment Test**

1161 To test whether strains from particular ecological origins were enriched for variants with
1162 significant effects in a particular direction in fluconazole, we first split the variants with
1163 significant fitness effects in fluconazole into positive and negative effect variants. We
1164 then checked for each strain in the 1,011 yeast genomes if they were homozygous or
1165 heterozygous for the alternate allele we edited in at each significant variant. For positive
1166 effect variants, strains with the alternate allele had 1 added to their score, and for
1167 negative effect alleles, strains with the alternate allele had 1 subtracted from their score.
1168 The total number of negative effect variants was added to this score for all strains, as
1169 any strain with the reference allele for those sites in effect had the positive effect allele.
1170 The 1,011 yeast strains were then sorted by this score, and the top 100 were chosen to
1171 look at their ecological origins, as they were presumably the strains with the most
1172 evidence for being under selection for increased growth in fluconazole. A hypergeometric
1173 test was performed to determine enrichment of the top categories, "Human" and
1174 "Human, clinical."

1175 **Detecting significant GxE interactions**

1176 The weighted least squares model described above detected variants with significant
1177 fitness effects in a given condition as well as variants with gene-by-environment effects;
1178 all pairwise differences in fitness effects between conditions (e.g. 15 differences for
1179 variants measured in six conditions) were calculated. The p-values were adjusted for
1180 multiple testing using the Benjamini-Hochberg procedure and significant differences
1181 were controlled at FDR = 0.01 (Benjamini and Hochberg, 1995). At this threshold, none
1182 of the neutral/non-cutting variants exhibited GxE interactions.

1183 **Permutation test for nonrandom clustering of GxE promoter variants**

1184 In order to test whether the level of clustering observed for hits in each annotation
1185 category at each distance was more than would be expected by chance, we permuted
1186 the hits 1000 times by choosing random variants of the same annotation to be hits,
1187 choosing the same number of promoter hits as exist in the real dataset, and then
1188 performing the same cluster analysis for these permuted sets. We then counted how
1189 many of these permuted data sets had greater than or equal to the number of genomic
1190 loci in clusters as the real data set to determine permutation p-values. For the final p-
1191 value for promoter variants at 8 bp, we performed 5000 permutations twice (two seeds).
1192 We then took the average of the two permutation p-values.

1193 **Clonal genotyping**

1194 Single CRISPEY-BAR oligonucleotides containing partial sequence containing 5'
1195 homology to pSAC200, 12 bp programmed barcode, restriction site region for cloning,
1196 108 bp donor template sequence and 34 bp constant region were ordered from IDT as
1197 dsDNA eblocks for individual validation of genotype correct strains. The eblocks were
1198 amplified using primer #576 as forward primer and donor specific primers that append
1199 the 20 bp guide sequence and 3' homology to pSAC200 to the eblocks. The resulting
1200 PCR products were bead purified and cloned into pSAC200, ligated with UMI-containing
1201 insert and transformed into yeast as described for library cloning above. The yeast
1202 transformants were induced for editing by culturing in 5 mL YNB -HIS -URA 2% raffinose
1203 media for 24 hr, passaged twice in 5 mL YNB -HIS -URA 2% galactose media for 24 hr
1204 each, then streaked out on YNB -URA 2% glucose (1.7g/L yeast nitrogen base (RPI); 5
1205 g/L Ammonium Sulfate (ACROS organics); 1.9 g Dropout synthetic mix minus uracil, w/o
1206 nitrogen base (US Biological) and 20 g/L glucose (Sigma) 2% agar plates to obtain
1207 single edited clones. plasmids were cured from edited clones by restreaking on YNB 2%
1208 glucose 2% agar plates with 1 g/L 5-Fluororotic acid monohydrate (GoldBio). The single
1209 plasmid-cured colonies were amplified by growing in YNB 2% glucose media overnight
1210 and stored in YNB 2% glucose media with 15% glycerol at -80°C.
1211 Colonies were streaked out from the frozen stock and lysed with Zymolyase 20T (US
1212 Biological) solution in 50 mM potassium phosphate buffer, pH 7.5. Cell lysates were
1213 used for genotyping using EmeraldAmp MAX PCR Mastermix (Takara), with primers
1214 #261 and #262 for determining barcode-UMI sequence and locus-specific primers

1215 (**Supplemental Table S1**). PCR cycles had an initial denaturation of 95°C for 2 min; then
1216 35 cycles of 95°C for 10 s, 60°C for 15 s, 72°C for 20 s; then a final extension of 72°C for
1217 5 min. PCR products were purified, Sanger sequenced and aligned to the reference
1218 genome using SGD BLAST to confirm the intended genotype (Cherry et al., 2012; Engel
1219 et al., 2014). For the QTL pools, colonies were randomly picked from edited cells plated
1220 on non-selective media after plasmid removal. Genomic amplicons of loci containing the
1221 associated variant edit were Sanger sequenced from barcoded colonies to calculate the
1222 editing rates shown in **Figure 1d**.

1223

1224 **qRT-PCR**

1225 Strains containing the Sanger sequencing-verified genotypes were thawed from frozen
1226 stock and grown overnight in 5 mL YNB 2% glucose media. 0.5 mL of the overnight
1227 culture was passaged to 50 mL YNB 2% glucose media with or without 30 mg/mL
1228 lovastatin. Cells were harvested after 5 generations of growth in media, approximately 12
1229 hr after passaging. RNA was extracted by vortexing with 500 uL glass beads and 1 mL
1230 Trizol (Invitrogen) by manufacturer's instructions. 8 ug total RNA of each sample were
1231 digested with RQ1 DNase for 1 hr at 37°C as manufacturer's instructions and purified by
1232 overnight ethanol precipitation. 400 ng of the purified RNA from each sample were
1233 converted to cDNA using Superscript IV First-Strand Synthesis system by
1234 manufacturer's instructions. qPCR was performed as described previously (Sharon et al.,
1235 2018). qPCR primers for ERG4 and ACT1 are included in Supplementary Table S1.

1236

1237 **Fitness validation**

1238 Strains containing the Sanger sequencing verified genotypes were thawed from frozen
1239 stock and grown overnight in SC media and mixed with the GFP control strain in 1 mL
1240 SC media with specified conditions in a 96-well plate. Cells were passaged every 12 hr
1241 and diluted to fresh 1 mL SC media with specified conditions. Six timepoints (T1-T6)
1242 were harvested once passage was complete. Harvested cells were spun down and
1243 resuspended in 1x DPBS (Gibco) and stored at 4°C and assayed by flow cytometry
1244 within 12 hr post-harvest. Generation time was estimated by measuring OD₆₀₀ of the
1245 culture containing ZRS111 and GFP control strain at every time point. Competition for

1246 each edited strain against GFP control strain was replicated four times in four different
1247 wells, to control for spontaneous mutation during competition.
1248 Ratios between each edited strain against GFP control strain were determined by flow
1249 cytometry assay, using an Attune NxT Flow Cytometer and Autosampler (ThermoFisher
1250 Scientific). GFP was detected using a 530 nm band-pass filter (BL1) with a 488 nm laser.
1251 The channel voltages were adapted from a previous study and set as follows: FSC: 200;
1252 SSC: 320; and BL1:480⁴¹. A threshold for FSC of 2.5×10^3 A.U. was applied to exclude
1253 non-yeast events. Data analysis was performed using Attune NxT Software v2.7.
1254 Doublets were removed by FSC gating and cell counts for GFP control strain were
1255 determined by BL1 gating and the remaining cells were counted as the non-fluorescent,
1256 corresponding to edited strains. Samples with fewer than 500 total cells gated, as well as
1257 samples with cell counts of less than 3 for either GFP or edited strains, were excluded.
1258 Log₂ ratios between edited strain count and GFP control strain count were calculated for
1259 each sample and fitted to a slope for the estimated generations within each replicate.
1260 The slopes were normalized by subtracting the slope calculated by the competition of a
1261 non-variant edit, barcode-only control to the GFP control strain in the same replicate.
1262 Finally, the mean and standard error for slopes across four replicates were calculated for
1263 each edited strain, representing pairwise fitness values.

1264

1265 **Data and Software Availability**

1266 All raw sequencing data have been deposited in the NCBI Sequence Read Ar-
1267 chive "PRJNA827354". All software and code used for the design and barcode-UMI
1268 count analysis are available upon request. Code used to create specific figures is availa-
1269 ble upon request. Sequences for oligonucleotides used in this study can be found in Ta-
1270 ble S1. Sanger sequencing data related to Figure 1e can be found at: Chen, Shi-An
1271 (2022), "Gene-by-environment interactions are pervasive among natural genetic vari-
1272 ants", Mendeley Data, V1, doi: 10.17632/sm32n7ms8h.1

1273

1274 **Supplementary Tables**

1275

1276 **Table S1. Plasmid sequences, primers and oligonucleotides used in this study.**

1277 This table contains 1) plasmid sequence used in this study; 2) primers used in this study;
1278 3) gblock oligonucleotides for individual validation used in this study; 4-7) synthesized ol-
1279 igonucleotide pools for CRISPEY-BAR used in this study, including pools for cobalt chlo-
1280 ride, caffeine, fluconazole and ergosterol pathway.

1281

1282 **Table S2. Assignment of array synthesized oligonucleotides for each CRISPEY-**

1283 **BAR pool by well number.** This table contains information for well pooling information,
1284 with each column contains the well IDs from synthesized oligonucleotide array assigned
1285 to each well.